ストックスクリーナーアプリを入手
7.60
1.13%
0.085
前日終値:
$7.515
開ける：
$7.61
24時間の取引高:
13,446
Relative Volume:
0.16
時価総額：
$42.19M
収益：
-
当期純損益:
$-16.35M
株価収益率:
-2.4918
EPS:
-3.05
ネットキャッシュフロー:
$-11.88M
1週間 パフォーマンス:
-5.35%
1か月 パフォーマンス:
+141.27%
6か月 パフォーマンス:
+144.37%
1年 パフォーマンス:
+43.67%
1日の値動き範囲:
$7.50
$7.7099
1週間の範囲:
$6.93
$8.3472
52週間の値動き範囲:
$2.52
$8.3472
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
7.60 | 41.72M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.17 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
797.25 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.56 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.86 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.78 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
How Lipocine Inc. stock reacts to global recession fears2026 world cup usa national team round of 16 young talents high defensive line expert forecast preview - Улправда
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
Aug PreEarnings: Can Lipocine Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
Market Pulse: How Lipocine Inc. stock reacts to global recession fearsWeekly Trade Report & Long Hold Capital Preservation Tips - Улправда
Can Lipocine Inc. stock outperform in 2025 bull marketMarket Sentiment Report & Weekly High Return Stock Opportunities - Улправда
Does Lipocine Inc. stock trade at a discount to peersJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
Return on equity % of Lipocine Inc. – BOATS:LPCN - TradingView — Track All Markets
Trend Review: Can Lipocine Inc. stock deliver consistent earnings growth2025 Valuation Update & Detailed Earnings Play Alerts - DonanımHaber
How Lipocine Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Fast Gain Stock Trading Tips - DonanımHaber
Financial Review: Lipocine (NASDAQ:LPCN) vs. Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Lipocine reaches 80% enrollment in postpartum depression drug trial By Investing.com - Investing.com Nigeria
Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks
Lipocine Inc Announces 80% Enrollment in PPD Phase 3 Study - TradingView — Track All Markets
Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com India
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Lipocine Inc. Announces Resignation of Jeffrey Fink as Director, Effective January 1, 2026 - marketscreener.com
Lipocine Earnings Notes - Trefis
Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting - Investing.com UK
EBIT per share of Lipocine Inc. – BOATS:LPCN - TradingView
Lipocine (LPCN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Can Lipocine Inc. stock sustain revenue growthJuly 2025 Weekly Recap & Community Consensus Stock Picks - newser.com
Will Lipocine Inc. stock outperform value stocksMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Can Lipocine Inc. stock resist sector downturnsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
How Lipocine Inc. stock reacts to inflationary pressuresOptions Play & Free Growth Oriented Trading Recommendations - newser.com
Smart tools for monitoring Lipocine Inc.’s price actionEarnings Summary Report & Community Driven Trade Alerts - newser.com
Is Lipocine Inc. stock a safe buy before earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Lipocine reports positive safety review for PPD treatment in phase 3 trial - Investing.com Nigeria
Lipocine Announces Positive Interim Results for PPD Trial - TipRanks
[8-K] Lipocine Inc. Reports Material Event | LPCN SEC FilingForm 8-K - Stock Titan
Lipocine highlights promising interim safety profile in phase 3 trial of LPCN 1154 in postpartum depression (PPD) - MarketScreener
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - The Herald Journal
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
大文字化:
|
ボリューム (24 時間):